Advertisement
NBIX or REPL or XOMA
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NBIX’s FA Score shows that 0 FA rating(s) are green whileREPL’s FA Score has 1 green FA rating(s), and XOMA’s FA Score reflects 1 green FA rating(s).
- NBIX’s FA Score: 0 green, 5 red.
- REPL’s FA Score: 1 green, 4 red.
- XOMA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NBIX’s TA Score shows that 4 TA indicator(s) are bullish while REPL’s TA Score has 4 bullish TA indicator(s), and XOMA’s TA Score reflects 4 bullish TA indicator(s).
- NBIX’s TA Score: 4 bullish, 4 bearish.
- REPL’s TA Score: 4 bullish, 4 bearish.
- XOMA’s TA Score: 4 bullish, 5 bearish.
Price Growth
NBIX (@Pharmaceuticals: Other) experienced а -0.60% price change this week, while REPL (@Biotechnology) price change was +16.06% , and XOMA (@Biotechnology) price fluctuated -3.97% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.97%. For the same industry, the average monthly price growth was +6.36%, and the average quarterly price growth was +73.05%.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.06%. For the same industry, the average monthly price growth was +13.62%, and the average quarterly price growth was +40.41%.
Reported Earning Dates
NBIX is expected to report earnings on Nov 04, 2025.
REPL is expected to report earnings on Nov 18, 2025.
XOMA is expected to report earnings on Nov 06, 2025.
Industries' Descriptions
@Pharmaceuticals: Other (-0.97% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Biotechnology (+2.06% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| NBIX | REPL | XOMA | |
| Capitalization | 13.7B | 964M | 318M |
| EBITDA | 358M | -235.43M | 6M |
| Gain YTD | -1.751 | 3.220 | 1.256 |
| P/E Ratio | 57.20 | N/A | N/A |
| Revenue | 1.89B | 0 | 13M |
| Total Cash | 1.03B | 484M | 92.6M |
| Total Debt | 428M | 76.2M | 114M |
NBIX | REPL | XOMA | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 71 | 26 | 18 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 72 Overvalued | 30 Undervalued | 2 Undervalued | |
PROFIT vs RISK RATING 1..100 | 82 | 100 | 84 | |
SMR RATING 1..100 | 61 | 98 | 93 | |
PRICE GROWTH RATING 1..100 | 50 | 38 | 47 | |
P/E GROWTH RATING 1..100 | 34 | 100 | 100 | |
SEASONALITY SCORE 1..100 | n/a | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
XOMA's Valuation (2) in the Biotechnology industry is in the same range as REPL (30) and is significantly better than the same rating for NBIX (72). This means that XOMA's stock grew similarly to REPL’s and significantly faster than NBIX’s over the last 12 months.
NBIX's Profit vs Risk Rating (82) in the Biotechnology industry is in the same range as XOMA (84) and is in the same range as REPL (100). This means that NBIX's stock grew similarly to XOMA’s and similarly to REPL’s over the last 12 months.
NBIX's SMR Rating (61) in the Biotechnology industry is in the same range as XOMA (93) and is somewhat better than the same rating for REPL (98). This means that NBIX's stock grew similarly to XOMA’s and somewhat faster than REPL’s over the last 12 months.
REPL's Price Growth Rating (38) in the Biotechnology industry is in the same range as XOMA (47) and is in the same range as NBIX (50). This means that REPL's stock grew similarly to XOMA’s and similarly to NBIX’s over the last 12 months.
NBIX's P/E Growth Rating (34) in the Biotechnology industry is significantly better than the same rating for REPL (100) and is significantly better than the same rating for XOMA (100). This means that NBIX's stock grew significantly faster than REPL’s and significantly faster than XOMA’s over the last 12 months.
| NBIX | REPL | XOMA | |
|---|---|---|---|
| RSI ODDS (%) | 2 days ago 57% | 2 days ago 90% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 61% | 2 days ago 80% | 2 days ago 81% |
| Momentum ODDS (%) | 2 days ago 69% | 2 days ago 82% | 2 days ago 83% |
| MACD ODDS (%) | 2 days ago 69% | 2 days ago 83% | 2 days ago 86% |
| TrendWeek ODDS (%) | 2 days ago 61% | 2 days ago 81% | 2 days ago 81% |
| TrendMonth ODDS (%) | 2 days ago 72% | 2 days ago 80% | 2 days ago 81% |
| Advances ODDS (%) | 8 days ago 72% | 2 days ago 78% | 8 days ago 79% |
| Declines ODDS (%) | 21 days ago 62% | 17 days ago 84% | 22 days ago 80% |
| BollingerBands ODDS (%) | 2 days ago 77% | 2 days ago 86% | 2 days ago 86% |
| Aroon ODDS (%) | 2 days ago 74% | 2 days ago 78% | 2 days ago 80% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| KSEP | 26.07 | 0.20 | +0.76% |
| Innovator U.S. Small Cp Pwr Buf ETF -Sep | |||
| PEY | 21.13 | 0.14 | +0.67% |
| Invesco High Yield Eq Div Achiev™ ETF | |||
| BUFG | 25.86 | 0.10 | +0.39% |
| FT Vest Buffered Allocation Gr ETF | |||
| MSTI | 20.55 | -0.01 | -0.05% |
| Madison Short-Term Strategic Income ETF | |||
| ULE | 12.94 | -0.07 | -0.56% |
| ProShares Ultra Euro | |||
XOMA and
Correlation & Price change
A.I.dvisor indicates that over the last year, XOMA has been loosely correlated with SYRE. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if XOMA jumps, then SYRE could also see price increases.
| Ticker / NAME | Correlation To XOMA | 1D Price Change % | ||
|---|---|---|---|---|
| XOMA | 100% | +1.33% | ||
| SYRE - XOMA | 39% Loosely correlated | +5.81% | ||
| YMAB - XOMA | 39% Loosely correlated | +3.08% | ||
| SPRY - XOMA | 37% Loosely correlated | +1.77% | ||
| GBIO - XOMA | 37% Loosely correlated | +32.63% | ||
| LGND - XOMA | 37% Loosely correlated | +4.29% | ||
More | ||||